GlassScriptPhysician profile
Kathleen A Kelley
NPI 1447479928
$9,613.20
in general payments reported to CMS, 2019-2025
10 companies · $676 in 2025
The $676 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2024: $8,830 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,350 · Food and Beverage: $1,292 · Travel and Lodging: $830 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,350.00 |
| Food and Beverage | $1,291.71 |
| Travel and Lodging | $829.87 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,500.85 | 2024 | |
| Madrigal Pharmaceuticals | $268.27 | 2025 | Rezdiffra |
| Becton, Dickinson and Company | $177.87 | 2024 | Arista Ah Flexitip |
| Glaxosmithkline, LLC. | $149.34 | 2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $123.76 | 2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Dupixent |
| Genzyme Corporation | $107.62 | 2022 | |
| Axsome Therapeutics, INC. | $100.69 | 2025 | Auvelity |
| Amgen INC. | $34.00 | 2025 | |
| Optinose US, INC. | $28.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.